ArticleVeterinary sciences2026
Revisiting Ki-67 Assessment in Canine Mast Cell Tumours: From Manual Hotspot to Automated Global Analysis.
Article in Veterinary sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Canine mast cell tumours (MCTs) show highly variable behaviour, and Ki-67 is an established prognostic indicator. Conventional Ki-67 assessment is manual and restricted to small hotspot areas, limiting reliability. This study presents a semi-automated whole-tumour tissue section (global) Ki-67 analysis workflow, outlines its limitations, and examines correlations with hotspot counts and clinical outcome. A total of 309 canine MCTs were assessed using a deep-learning-assisted quantification with commercial software. Global Ki-67 metrics were correlated with hotspot Ki-67 counts and histomorphologic tumour grades, as supported by clinical follow-up data from 68 dogs. The defined analytic workflow enabled an overall feasible global Ki-67 assessment in canine MCTs. The region-of-interest (ROI) definition required frequent manual adjustments, whereas Ki-67 quantification was fully automated and rapid. Global Ki-67 metrics correlated with manual hotspot counts, with Ki-67-positive cell density on average twice as high in tumour hotspots compared with whole tumour sections, with differences ranging up to 38-fold. Exploratory survival analyses suggested promising predictive power, warranting validation in a robust survival study. With established digital pathology tools, global whole-tumour assessment of Ki-67 and other biomarkers is feasible. It should become the new standard for defining robust prognostic and predictive markers in canine mast cell and other tumours.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.